Back
Mémoire
Bachelor thesis

CROs : the best way to dynamize the pharmaceutical industry ?

SONAR|HES-SO

    2013

46 p.

Mémoire de bachelor: Haute école de gestion de Genève, 2013

Industrie pharmaceutique
Gestion du risque
Planification stratégique
English This Bachelor’s Project examines some of the main obstacles opposing the pharmaceutical industry today. They may be identified as follow: 1. Low shareholder or stakeholder value delivery 2. Low growth environment 3. Stagnating R&D productivity 4. Growing risk and damaged trust I postulate that the pharmaceutical industry has a substantial chance to redress itself in the eyes of shareholders or stakeholders, succeeding to surface in the current unsatisfactory business climate. Vegetating Occidental markets, shared with growing Emerging Markets, will alter both the formula as well as the wishes of the industry. The growth of Emerging Markets will generate and increase sales, though will also lead to a reduction in margins. R&D productivity has been substandard in the last years, and the dynamics will need to change, for the industry to carry on with extensive growth. The approval rates, granted by the FDA, have provoked a great number of molecules to fail in the quest of reaching the market. Several risks have been rising and disturbing the evolution of the pharmaceuticals. These are namely scientific, political, legal, and image-related risks. These menaces have brought pharmaceuticals to invest their time and money on matters that could have been mitigated by means of additional testing or deepened market research. I believe that, throughout the course of this paper, a number of solutions may be identified to deliver new dynamics to this suffering industry. Since pharmaceuticals aspire to reduce costs and to accelerate their drug development process, they may request the assistance of CROs, specialized in R&D activities. This will lead to an enhancement of pipelines, an improvement in R&D productivity, an increase in savings, and a provision to the pharmaceuticals of additional solutions in their pursuit of delivering medication to the markets in a timely manner. The industry will respond positively to their issues with the help of innovative solutions that CROs propose. I am of the opinion that collaboration between a pharmaceutical and a CRO may only be a positive one, because it would accommodate the alignment of expertise, qualified staff, and facilities for a structure that is currently in dire need of these.
Language
  • English
Classification
Economics
Notes
  • Haute école de gestion Genève
  • Economie d'entreprise
  • hesso:hegge
License
License undefined
Identifiers
  • RERO DOC 209155
  • RERO R007610168
Persistent URL
https://sonar.ch/global/documents/314402
Statistics
Document views: 90 File downloads:
  • TDEE_Jean_Philippe_Lutz.pdf: 128